|Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|Outline of Final Research Achievements
We hypothesized that the resistance of sorafenib treatment in hepatocellular carcinoma occurs by increasing PD-L1 expression that is directly enhanced by HIF1α. We cultured hepatocellular carcinoma cell lines using cobalt addition or a hypoxic chamber, and compared with control cell lines cultured under normoxia. HIF1α was upregulated in the culture with cobalt and hypoxia chamber. However, PD-L1 expression was not enhanced by either RT-PCR or Western blotting. PD-L1 expression was enhanced by adding IFNγ to hepatocellular carcinoma cell lines and was further enhanced by the addition of cobalt.